Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2025-09-24 Capital/Financing Update
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 90% confidence The document is a ‘주요사항보고서’ detailing the decision to issue convertible bonds by 현대바이오사이언스주식회사, including terms, interest schedule, conversion price adjustments, put and call options, and collateral. This is a direct announcement of a new financing transaction (debt issuance convertible into equity), i.e. a capital/financing update. Therefore, it should be classified under Capital/Financing Update (CAP).
2025-09-24 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status, changes in ownership, and collateral agreements of major shareholders (CnPharm Co., Ltd. and related parties) in Hyundai Bioscience. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-09-16 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (뎅기 또는 뎅기 유사 질환 환자를 대상으로 CPCOV03의 2/3상 임상시험계획 변경승인 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (Hyundai Bioscience) submitted to the Korea Exchange (KRX). It details a 'Major Management Matter' regarding an application for an amendment to a clinical trial plan (CP-COV03). Since this is a specific regulatory disclosure regarding clinical trial status and does not fit into categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate disclosures.
2025-09-16 Korean
투자판단관련주요경영사항(임상시험계획변경승인) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Hyundai Bioscience) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the approval of a clinical trial plan change for a prostate cancer treatment. This type of disclosure is a standard regulatory announcement in the Korean market (KOSDAQ/KRX) regarding material business developments. Since it does not fit into specific categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category.
2025-09-08 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Hyundai Bioscience regarding a 'Major Management Matter' (Investment Judgment), specifically an application for approval to change a clinical trial plan for a prostate cancer treatment. It details the clinical trial objectives, methodology, and the reason for the change (transfer of clinical trial sponsor status). As this is a formal regulatory disclosure of a material event (clinical trial status update) that does not fit into specific categories like earnings releases or annual reports, it is classified as a Regulatory Filing (RNS).
2025-09-02 Korean
[기재정정]사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a 'Correction Report' (정정신고) for an 'Annual Report' (사업보고서) filed by Hyundai Bioscience. It explicitly states the document type as '사업보고서' (Business Report/Annual Report) and provides a correction to the research and development expenses section of the previously submitted annual report. Since this is a formal amendment to an existing annual report containing financial data and management disclosures, it is classified under the 10-K category. FY 2024
2025-08-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.